Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal Melanoma
Source: Pharmacy Times, October 2022
The agent is representative of a new class of drug, ImmTAC.
In January 2022, the FDA approved tebentafusp-tebn (Kimmtrak; Immunocore) for the treatment of adult patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma. The FDA approval was based on results from the IMCgp100 102 trial (NCT02570308), a phase 3, open-label, multicenter trial that included 378 patients with metastatic uveal melanoma.
Uveal melanoma is the most common intraocular cancer in adults and represents 3% to 5% of all melanomas, with an annual incidence in Europe and the United States at approximately 6 per 1 million individuals annually. Additionally, up to 50% of patients with uveal melanoma will have metastases, predominantly in the liver. The median overall survival in the metastatic setting is approximately 1 year with current agents.